Skip to main
BCYC

BCYC Stock Forecast & Price Target

BCYC Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 11%
Buy 44%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Bicycle Therapeutics PLC is poised for a positive outlook due to the potential for enhanced efficacy in its combination therapies, specifically the BT1718 candidate, which could attract significant patient switches from existing treatments based on improved safety profiles. The company's innovative design of Bicycles allows for superior tumor targeting and safety, suggesting a competitive edge compared to earlier treatments in oncology, particularly in promising early indicators for the BT5528 candidate. Furthermore, the anticipated strong clinical validation outcomes and the expected commercial adoption of its products position Bicycle Therapeutics favorably within the biopharmaceutical market, tapping into high unmet medical needs in oncology across both the United Kingdom and the United States.

Bears say

Bicycle Therapeutics PLC faces significant uncertainties related to its competitive positioning and product pipeline, as illustrated by its BT1718 candidate's challenges in demonstrating viability against established therapies, which has contributed to stock weakness. The company's decision to deprioritize the BT7480 program reflects broader industry trends and potential setbacks in advancing combination therapies, which may hinder its revenue prospects. Additionally, risks surrounding negative trial outcomes, slower enrollment rates, and possible adverse regulatory outcomes could obstruct the pathway to commercialization, further diminishing investor confidence in the firm's market potential.

BCYC has been analyzed by 9 analysts, with a consensus rating of Buy. 11% of analysts recommend a Strong Buy, 44% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicycle Therapeutics Plc - ADR (BCYC) Forecast

Analysts have given BCYC a Buy based on their latest research and market trends.

According to 9 analysts, BCYC has a Buy consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicycle Therapeutics Plc - ADR (BCYC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.